The Popular Parliamentary Group has presented a battery of parliamentary questions in Congress among which it is interested in the criteria that the Government would take into account in the event that, when the time comes, not enough doses of the coronavirus vaccine are acquired and it is necessary to establish priorities in the population, in line with a concern expressed by the president of the Spanish Bioethics Committee.

In the explanatory statement it is noted that on June 17, 2020, an interview was published in the press in which Federico de Montalvo, president of the Bioethics Committee of Spain, proposed, in the context of the crisis generated by COVID-19 , your doubts about whether the application of the vaccine in Spanish society will generate prioritization problems in society, raising the following question: If we get 20 million doses, who do we give the vaccine to?

For this reason, the PP deputy secretaries Cuca Gamarra, Jaime de Olano and Elvira Rodríguez, the deputy to the GPP General Secretariat, Isabel Borrego, the deputy spokespersons José Ignacio Echániz and Mario Garcés, the GPP spokesperson in the Reconstruction Commission and vice president second from Congress, Ana Pastor, the president of the Health Commission, Rosa Romero, the GPP's health spokesperson, Elvira Velasco, and deputies Juan Antonio Callejas and Agustín Almodóbar, ask the following questions to the Executive:

-Is the government planning to promote at any time any measure to avoid the feared problems from the Spanish Bioethics Committee that when the time has come to vaccinate against the COVID-19 pandemic, do not acquire enough doses of the vaccine and should we prioritize some citizens over others?

-If so, what measures do you plan to develop? In what actual time frames? Will the Government coordinate these measures with the Autonomous Communities?

-If the situation arose, what criteria would the government take into account to establish the citizens who would have priority in access to the vaccine?




Source of new

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *